Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events

Pedersen BK . A muscular twist on the fate of fat. N Engl J Med 2012; 366: 1544–1545.

Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463–468.

Gesta S, Tseng YH, Kahn CR . Developmental origin of fat: tracking obesity to its source. Cell 2007; 131: 242–256.

Stanford KI, Middelbeek RJ, Townsend KL, An D, Nygaard EB, Hitchcox KM et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest 2013; 123: 215–223.

Yang X, Enerback S, Smith U . Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance. Obes Res 2003; 11: 1182–1191.

Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF . Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index. Peptides 2013; 39: 125–130.

Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899–4907.

Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365–369.

Polyzos SA, Kountouras J, Shields K, Mantzoros CS . Irisin: a renaissance in metabolism? Metabolism 2013; 62: 1037–1044.

Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 2013; 34: 377–412.

Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB . Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

Nikolopoulou A, Kadoglou NP . Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther 2012; 10: 933–939.

Targher G, Day CP, Bonora E . Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341–1350.

Bhatia LS, Curzen NP, Calder PC, Byrne CD . Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190–1200.

Lecker SH, Zavin A, Cao P, Arena R, Allsup K, Daniels KM et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail 2012; 5: 812–818.

Bell B, Rose CL, Damon A . The Veterans Administration longitudinal study of healthy aging. Gerontologist 1966; 6: 179–184.

Deurenberg P, Weststrate JA, Seidell JC . Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 1991; 65: 105–114.

de la Hera JM, Delgado E, Hernandez E, Garcia-Ruiz JM, Vegas JM, Avanzas P et al. Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. Eur Heart J 2009; 30: 2614–2621.

Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634–2653.

Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725–1738.

Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS . Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2013; 163: 207–217.

Mantzoros CS, Liolios AD, Tritos NA, Kaklamani VG, Doulgerakis DE, Griveas I et al. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res 1998; 6: 179–186.

Shea SA, Hilton MF, Orlova C, Ayers RT, Mantzoros CS . Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005; 90: 2537–2544.

Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

Timmons JA, Baar K, Davidsen PK, Atherton PJ . Is irisin a human exercise gene? Nature 2012; 488: E9–10 (Discussion E10-1).

Swick AG, Orena S, O'Connor A . Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism 2013; 62: 1070–1073.

Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769–E778.

Roberts MD, Bayless DS, Company JM, Jenkins NT, Padilla J, Childs TE et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 2013; 62: 1052–1056.

Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96–101.

Vamvini MT, Aronis KN, Panagiotou G, Huh JY, Chamberland JP, Brinkoetter MT et al. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol 2013; 169: 829–834.

Bostrom PA, Fernandez-Real JM, Mantzoros C . Irisin in humans: recent advances and questions for future research. Metabolism 2014; 63: 178–180.

Gouni-Berthold I, Berthold HK, Huh JY, Berman R, Spenrath N, Krone W et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 2013; 8: e72858.

Fain JN, Company JM, Booth FW, Laughlin MH, Padilla J, Jenkins NT et al. Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs. Metabolism 2013; 62: 1503–1511.